Literature DB >> 25894672

More similar than different: Host cell protein production using three null CHO cell lines.

Inn H Yuk1, Julie Nishihara2, Donald Walker2, Eric Huang3, Feny Gunawan4, Jayashree Subramanian3, Abigail F J Pynn3, X Christopher Yu2, Judith Zhu-Shimoni2, Martin Vanderlaan4, Denise C Krawitz4.   

Abstract

To understand the diversity in the cell culture harvest (i.e., feedstock) provided for downstream processing, we compared host cell protein (HCP) profiles using three Chinese Hamster Ovary (CHO) cell lines in null runs which did not generate any recombinant product. Despite differences in CHO lineage, upstream process, and culture performance, the cell lines yielded similar cell-specific productivities for immunogenic HCPs. To compare the dynamics of HCP production, we searched for correlations between the time-course profiles of HCP (as measured by multi-analyte ELISA) and those of two intracellular HCP species, phospholipase B-like 2 (PLBL2) and lactate dehydrogenase (LDH). Across the cell lines, proteins in the day 14 supernatants analyzed by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) showed different spot patterns. However, subsequent analysis by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) indicated otherwise: the total number of peptides and proteins identified were comparable, and 80% of the top 1,000 proteins identified were common to all three lines. Finally, to assess the impact of culture viability on extracellular HCP profiles, we analyzed supernatants from a cell line whose viability dropped after day 10. The amounts of HCP and PLBL2 (quantified by their respective ELISAs) as well as the numbers and major populations of HCPs (identified by LC-MS/MS) were similar across days 10, 14, and 17, during which viabilities declined from ∼80% to <20% and extracellular LDH levels increased several-fold. Our findings indicate that the CHO-derived HCPs in the feedstock for downstream processing may not be as diverse across cell lines and upstream processes, or change as dramatically upon viability decline as originally expected. In addition, our findings show that high density CHO cultures (>10(7) cells/mL)-operated in fed-batch mode and exhibiting high viabilities (>70%) throughout the culture duration-can accumulate a considerable amount of immunogenic HCP (∼1-2 g/L) in the extracellular environment at the time of harvest (day 14). This work also demonstrates the potential of using LC-MS/MS to overcome the limitations associated with ELISA and 2D-PAGE for HCP analysis.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  CHO host cell protein; ELISA; LC-MS/MS; PLBL2; orthogonal methods; proteomics

Mesh:

Substances:

Year:  2015        PMID: 25894672     DOI: 10.1002/bit.25615

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  14 in total

1.  Toward the complete characterization of host cell proteins in biotherapeutics via affinity depletions, LC-MS/MS, and multivariate analysis.

Authors:  James A Madsen; Victor Farutin; Theresa Carbeau; Steve Wudyka; Yan Yin; Stephen Smith; James Anderson; Ishan Capila
Journal:  MAbs       Date:  2015-08-20       Impact factor: 5.857

2.  A modular and adaptive mass spectrometry-based platform for support of bioprocess development toward optimal host cell protein clearance.

Authors:  Donald E Walker; Feng Yang; Joseph Carver; Koman Joe; David A Michels; X Christopher Yu
Journal:  MAbs       Date:  2017-03-27       Impact factor: 5.857

3.  In-Line Monitoring of Downstream Purification Processes for VSV Based SARS-CoV-2 Vaccine Using a Novel Technique.

Authors:  Arik Makovitzki; Avital Jayson; Ziv Oren; Elad Lerer; Yaron Kafri; Eyal Dor; Lilach Cherry; Hanan Tzadok; Lilach Levin; Ophir Hazan; Irit Simon; Arnon Tal; Meni Girshengorn; Osnat Rosen
Journal:  BioTech (Basel)       Date:  2021-11-03

4.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Authors:  Nicola A Hanania; Michael Noonan; Jonathan Corren; Phillip Korenblat; Yanan Zheng; Saloumeh K Fischer; Melissa Cheu; Wendy S Putnam; Elaine Murray; Heleen Scheerens; Cecile T J Holweg; Romeo Maciuca; Sarah Gray; Ramona Doyle; Dana McClintock; Julie Olsson; John G Matthews; Karl Yen
Journal:  Thorax       Date:  2015-05-22       Impact factor: 9.139

5.  Influence of Escherichia coli chaperone DnaK on protein immunogenicity.

Authors:  Kirsty D Ratanji; Jeremy P Derrick; Ian Kimber; Robin Thorpe; Meenu Wadhwa; Rebecca J Dearman
Journal:  Immunology       Date:  2016-12-07       Impact factor: 7.397

6.  Effects of lysosomal biotherapeutic recombinant protein expression on cell stress and protease and general host cell protein release in Chinese hamster ovary cells.

Authors:  Damiano Migani; C Mark Smales; Daniel G Bracewell
Journal:  Biotechnol Prog       Date:  2017-03-29

7.  ELISA reagent coverage evaluation by affinity purification tandem mass spectrometry.

Authors:  Scott M Henry; Elissa Sutlief; Oscar Salas-Solano; John Valliere-Douglass
Journal:  MAbs       Date:  2017-07-14       Impact factor: 5.857

8.  Multiplexed Microfluidic Cartridge for At-Line Protein Monitoring in Mammalian Cell Culture Processes for Biopharmaceutical Production.

Authors:  Inês F Pinto; Ruben R G Soares; Meeri E-L Mäkinen; Veronique Chotteau; Aman Russom
Journal:  ACS Sens       Date:  2021-03-16       Impact factor: 7.711

9.  Quantitative definition and monitoring of the host cell protein proteome using iTRAQ - a study of an industrial mAb producing CHO-S cell line.

Authors:  Lesley M Chiverton; Caroline Evans; Jagroop Pandhal; Andrew R Landels; Byron J Rees; Peter R Levison; Phillip C Wright; C Mark Smales
Journal:  Biotechnol J       Date:  2016-06-22       Impact factor: 4.677

10.  Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development.

Authors:  Rosalynn Molden; Mengqi Hu; Sook Yen E; Diana Saggese; James Reilly; John Mattila; Haibo Qiu; Gang Chen; Hanne Bak; Ning Li
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.